5,289 Shares in Novartis AG (NYSE:NVS) Bought by Sivia Capital Partners LLC

Sivia Capital Partners LLC acquired a new stake in shares of Novartis AG (NYSE:NVS) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 5,289 shares of the company’s stock, valued at approximately $534,000.

Other hedge funds have also bought and sold shares of the company. Frazier Financial Advisors LLC purchased a new stake in Novartis in the fourth quarter worth about $26,000. Richardson Financial Services Inc. acquired a new position in Novartis in the 4th quarter worth approximately $26,000. Operose Advisors LLC acquired a new position in Novartis in the 3rd quarter worth approximately $28,000. Planned Solutions Inc. purchased a new stake in Novartis in the 4th quarter worth approximately $31,000. Finally, AdvisorNet Financial Inc boosted its position in Novartis by 480.0% in the 4th quarter. AdvisorNet Financial Inc now owns 348 shares of the company’s stock worth $35,000 after purchasing an additional 288 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Stock Performance

NVS traded down $0.75 during trading on Monday, hitting $104.97. 426,519 shares of the stock were exchanged, compared to its average volume of 1,483,195. The firm has a market capitalization of $214.56 billion, a P/E ratio of 14.27, a PEG ratio of 1.62 and a beta of 0.58. The company has a quick ratio of 0.71, a current ratio of 0.90 and a debt-to-equity ratio of 0.43. The stock has a fifty day moving average price of $99.84 and a two-hundred day moving average price of $100.63. Novartis AG has a 1-year low of $92.19 and a 1-year high of $108.78.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, April 23rd. The company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.73 by $0.07. Novartis had a net margin of 31.33% and a return on equity of 32.15%. The company had revenue of $11.83 billion during the quarter, compared to the consensus estimate of $11.50 billion. As a group, sell-side analysts predict that Novartis AG will post 7.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NVS. BMO Capital Markets increased their target price on Novartis from $114.00 to $116.00 and gave the company a “market perform” rating in a research report on Wednesday, April 24th. The Goldman Sachs Group initiated coverage on Novartis in a research note on Thursday, May 30th. They issued a “buy” rating and a $120.00 target price for the company. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $116.67.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.